Cargando…

Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation

BACKGROUND: Clinical severity of hemophilia A (HA) varies, possibly due to interplay of many factors in the hemostatic pathway. Pharmacokinetic monitoring of factor VIII (FVIII) replacement therapy in HA patients consists of measuring FVIII activity levels and subsequent dose adjustment. The Nijmege...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valke, Lars L.F.G., Bukkems, Laura H., Barteling, Wideke, Laros‐van Gorkom, Britta A.P., Blijlevens, Nicole M.A., Mathôt, Ron A.A., van Heerde, Waander L., Schols, Saskia E.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	HAEMOSTASIS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756259/ https://www.ncbi.nlm.nih.gov/pubmed/32979031 http://dx.doi.org/10.1111/jth.15106

Ejemplares similares

Combining factor VIII levels and thrombin/plasmin generation: A population pharmacokinetic‐pharmacodynamic model for patients with haemophilia A
por: Bukkems, Laura H., et al.
Publicado: (2022)

Von Willebrand disease type 2M: Correlation between genotype and phenotype
por: Maas, Dominique P. M. S. M., et al.
Publicado: (2021)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

Differences in thrombin and plasmin generation potential between East African and Western European adults: The role of genetic and non‐genetic factors
por: Temba, Godfrey S., et al.
Publicado: (2022)

One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P(®)/Humate P(®) treatment in von Willebrand disease patients
por: de Jager, Nico C. B., et al.
Publicado: (2019)

Treatment of patients with rare bleeding disorders in the Netherlands: Real‐life data from the RBiN study
por: Maas, Dominique P. M. S. M., et al.
Publicado: (2022)

Treatment‐related risk factors for inhibitor development in non‐severe hemophilia A after 50 cumulative exposure days: A case‐control study
por: Abdi, Amal, et al.
Publicado: (2021)

Validation of PROMIS Profile‐29 in adults with hemophilia in the Netherlands
por: van Balen, Erna C., et al.
Publicado: (2021)

Fibrinolytic assays in bleeding of unknown cause: Improvement in diagnostic yield
por: Valke, Lars L. F. G., et al.
Publicado: (2022)

Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972–2019
por: Hassan, Shermarke, et al.
Publicado: (2021)

Thrombin generation assays to personalize treatment in bleeding and thrombotic diseases
por: Valke, Lars L. F. G., et al.
Publicado: (2022)

Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001–2018
por: Hassan, Shermarke, et al.
Publicado: (2020)

Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency
por: Saes, Joline L., et al.
Publicado: (2019)

Joint status of patients with nonsevere hemophilia A
por: Zwagemaker, Anne‐Fleur, et al.
Publicado: (2022)

Kallikrein augments the anticoagulant function of the protein C system in thrombin generation
por: Wan, Jun, et al.
Publicado: (2021)

In patients with hemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype
por: Verhagen, Marieke J.A., et al.
Publicado: (2023)

The experiences and attitudes of hemophilia carriers around pregnancy: A qualitative systematic review
por: Punt, Marieke C., et al.
Publicado: (2020)

Clot stability as a determinant of effective factor VIII replacement in hemophilia A
por: Leong, Lilley, et al.
Publicado: (2017)

Genetic analysis of carrier status in female members of Japanese hemophilia families
por: Shinozawa, Keiko, et al.
Publicado: (2021)

A novel assay for studying the involvement of blood cells in whole blood thrombin generation
por: Wan, Jun, et al.
Publicado: (2020)

Characterization of interaction between blood coagulation factor VIII and LRP1 suggests dynamic binding by alternating complex contacts
por: Chun, Haarin, et al.
Publicado: (2022)

Whole blood thrombin generation profiles of patients with cirrhosis explored with a near patient assay
por: Wan, Jun, et al.
Publicado: (2020)

Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort
por: Pasi, K. John, et al.
Publicado: (2021)

Thrombin‐generating potential, plasma clot formation, and clot lysis are impaired in patients with bleeding of unknown cause
por: Hofer, Stefanie, et al.
Publicado: (2019)

SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders
por: Cnossen, Marjon H., et al.
Publicado: (2022)

Validity and reliability of the Colorado Adult Joint Assessment Scale in adults with moderate‐severe hemophilia A
por: Funk, Sharon M., et al.
Publicado: (2019)

Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non‐severe haemophilia A
por: Rejtő, Judit, et al.
Publicado: (2020)

Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach
por: Winterling, Karina, et al.
Publicado: (2021)

Thrombin generation for monitoring hemostatic therapy in hemophilia A: A narrative review
por: Verhagen, Marieke J. A., et al.
Publicado: (2022)

Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses
por: Kjalke, Marianne, et al.
Publicado: (2021)

Detailed analysis of anti‐emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A
por: Kaneda, Makoto, et al.
Publicado: (2021)

Management of von Willebrand disease with a factor VIII‐poor von Willebrand factor concentrate: Results from a prospective observational post‐marketing study
por: Goudemand, Jenny, et al.
Publicado: (2020)

Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)
por: Klamroth, Robert, et al.
Publicado: (2019)

Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Identification of deep intronic individual variants in patients with hemophilia A by next‐generation sequencing of the whole factor VIII gene
por: Inaba, Hiroshi, et al.
Publicado: (2017)

Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
por: Coyle, T E, et al.
Publicado: (2014)

Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
por: Bukkems, Laura H., et al.
Publicado: (2022)

Limited factor VIIa surface localization requirement of the factor VIIa–induced overall thrombin generation in platelet‐rich hemophilia A plasma
por: Persson, Egon, et al.
Publicado: (2019)

Acquired von Willebrand Disease Associated with Mantle Cell Lymphoma
por: Maas, Dominique, et al.
Publicado: (2018)

Salivary tissue factor induces thrombin generation in a diurnal rhythm
por: van der Vorm, Lisa N., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pa1uiuqkeafcj7fi8dil36biol